Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles.

Rodallec A, Sicard G, Fanciullino R, Benzekry S, Lacarelle B, Milano G, Ciccolini J.

Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1139-1147. doi: 10.1080/17425255.2018.1540588. Epub 2018 Oct 29. Review.

2.

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.

Rodallec A, Benzekry S, Lacarelle B, Ciccolini J, Fanciullino R.

Crit Rev Oncol Hematol. 2018 Sep;129:1-12. doi: 10.1016/j.critrevonc.2018.06.008. Epub 2018 Jun 19. Review.

PMID:
30097227
3.

Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach.

Benguigui M, Alishekevitz D, Timaner M, Shechter D, Raviv Z, Benzekry S, Shaked Y.

Oncotarget. 2017 Dec 20;9(2):2574-2590. doi: 10.18632/oncotarget.23514. eCollection 2018 Jan 5.

4.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50. doi: 10.1002/psp4.12265. Epub 2017 Dec 7.

5.

Mathematical Modeling of Tumor-Tumor Distant Interactions Supports a Systemic Control of Tumor Growth.

Benzekry S, Lamont C, Barbolosi D, Hlatky L, Hahnfeldt P.

Cancer Res. 2017 Sep 15;77(18):5183-5193. doi: 10.1158/0008-5472.CAN-17-0564. Epub 2017 Jul 20.

6.

Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas.

Henares-Molina A, Benzekry S, Lara PC, García-Rojo M, Pérez-García VM, Martínez-González A.

PLoS One. 2017 Jun 1;12(6):e0178552. doi: 10.1371/journal.pone.0178552. eCollection 2017.

7.

Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.

Mollard S, Ciccolini J, Imbs DC, El Cheikh R, Barbolosi D, Benzekry S.

Oncotarget. 2017 Apr 4;8(14):23087-23098. doi: 10.18632/oncotarget.15484.

8.

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.

Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S.

Ecancermedicalscience. 2016 Nov 2;10:689. eCollection 2016.

9.

In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling.

Mollard S, Fanciullino R, Giacometti S, Serdjebi C, Benzekry S, Ciccolini J.

Sci Rep. 2016 Nov 4;6:36173. doi: 10.1038/srep36173.

10.

Capturing the Driving Role of Tumor-Host Crosstalk in a Dynamical Model of Tumor Growth.

Benzekry S, Beheshti A, Hahnfeldt P, Hlatky L.

Bio Protoc. 2015 Nov 5;5(21). pii: e1644.

11.

Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.

Serre R, Benzekry S, Padovani L, Meille C, André N, Ciccolini J, Barlesi F, Muracciole X, Barbolosi D.

Cancer Res. 2016 Sep 1;76(17):4931-40. doi: 10.1158/0008-5472.CAN-15-3567. Epub 2016 Jun 14.

12.

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.

Arbel Y, Klempfner R, Erez A, Goldenberg I, Benzekry S, Shlomo N, Fisman EZ, Tenenbaum A; BIP Study Group.

Cardiovasc Diabetol. 2016 Jan 22;15:11. doi: 10.1186/s12933-016-0332-6.

13.

Computational Modelling of Metastasis Development in Renal Cell Carcinoma.

Baratchart E, Benzekry S, Bikfalvi A, Colin T, Cooley LS, Pineau R, Ribot EJ, Saut O, Souleyreau W.

PLoS Comput Biol. 2015 Nov 23;11(11):e1004626. doi: 10.1371/journal.pcbi.1004626. eCollection 2015 Nov.

14.

Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.

Benzekry S, Tracz A, Mastri M, Corbelli R, Barbolosi D, Ebos JM.

Cancer Res. 2016 Feb 1;76(3):535-47. doi: 10.1158/0008-5472.CAN-15-1389. Epub 2015 Oct 28.

15.

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N, Ciccolini J.

Semin Cancer Biol. 2015 Dec;35:53-61. doi: 10.1016/j.semcancer.2015.09.002. Epub 2015 Sep 7. Review.

PMID:
26361213
16.

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.

Ciccolini J, Benzekry S, Lacarelle B, Barbolosi D, Barlési F.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16. No abstract available.

17.

Design principles for cancer therapy guided by changes in complexity of protein-protein interaction networks.

Benzekry S, Tuszynski JA, Rietman EA, Lakka Klement G.

Biol Direct. 2015 May 28;10:32. doi: 10.1186/s13062-015-0058-5.

18.

Host age is a systemic regulator of gene expression impacting cancer progression.

Beheshti A, Benzekry S, McDonald JT, Ma L, Peluso M, Hahnfeldt P, Hlatky L.

Cancer Res. 2015 Mar 15;75(6):1134-43. doi: 10.1158/0008-5472.CAN-14-1053. Epub 2015 Mar 2.

19.

Classical mathematical models for description and prediction of experimental tumor growth.

Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JM, Hlatky L, Hahnfeldt P.

PLoS Comput Biol. 2014 Aug 28;10(8):e1003800. doi: 10.1371/journal.pcbi.1003800. eCollection 2014 Aug.

20.

Global dormancy of metastases due to systemic inhibition of angiogenesis.

Benzekry S, Gandolfi A, Hahnfeldt P.

PLoS One. 2014 Jan 21;9(1):e84249. doi: 10.1371/journal.pone.0084249. eCollection 2014.

21.

Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.

Benzekry S, Hahnfeldt P.

J Theor Biol. 2013 Oct 21;335:235-44. doi: 10.1016/j.jtbi.2013.06.036. Epub 2013 Jul 11.

22.

Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.

Lignet F, Benzekry S, Wilson S, Billy F, Saut O, Tod M, You B, Adda Berkane A, Kassour S, Wei MX, Grenier E, Ribba B.

J Theor Biol. 2013 Mar 7;320:86-99. doi: 10.1016/j.jtbi.2012.12.013. Epub 2012 Dec 21.

PMID:
23261980
23.

Passing to the limit 2D-1D in a model for metastatic growth.

Benzekry S.

J Biol Dyn. 2012;6 Suppl 1:19-30. doi: 10.1080/17513758.2011.568071. Epub 2011 Jun 24.

PMID:
22873672

Supplemental Content

Loading ...
Support Center